Can-Fite BioPharma Stock Scheduled to Reverse Split on Monday, January 5th (NYSE:CANF)

Can-Fite BioPharma Ltd. (NYSE:CANF) shares are going to reverse split on Monday, January 5th. The 1-20 reverse split was announced on Tuesday, December 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, January 4th.

Can-Fite BioPharma Price Performance

Can-Fite BioPharma stock traded up $0.01 during midday trading on Tuesday, reaching $0.18. 1,031,400 shares of the company traded hands, compared to its average volume of 2,544,944. The business has a 50 day moving average of $0.35 and a two-hundred day moving average of $0.62. The firm has a market capitalization of $4.74 million, a price-to-earnings ratio of -0.10 and a beta of 0.98. Can-Fite BioPharma has a 12 month low of $0.17 and a 12 month high of $2.33.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $2.50 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 4th. Zacks Research upgraded Can-Fite BioPharma to a “hold” rating in a research note on Thursday, November 6th. D. Boral Capital reduced their target price on Can-Fite BioPharma from $11.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Finally, D Boral Capital downgraded Can-Fite BioPharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 24th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $3.25.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers lifted its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 38,268 shares of the company’s stock after purchasing an additional 11,388 shares during the quarter. Rhumbline Advisers owned about 1.08% of Can-Fite BioPharma worth $57,000 as of its most recent filing with the SEC. 21.00% of the stock is currently owned by institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).